MoonLake Immunotherapeutics (NASDAQ: MLTX) stock rose 15.87% on Thursday, Oct. 22, 2026, to 12.34 USD, and is up 19.57% from the Oct. 20 close over two sessions. Benzinga, citing Benzinga Pro data, reported that the stock traded higher on volume well above its average. The company reports no revenue on its income statement and has sizable cash, so a move this large matters for anyone holding a small-cap biotech.
Key facts
- Oct. 22, 2026: MLTX was at 12.34 USD on the latest quote, up 15.87% on the day.
- Two sessions: the stock is up 19.57% from the Oct. 20, 2026 close to the latest quote.
- Size: market capitalization (share price times shares outstanding) is about $1.05B. The 52-week range is 9.31 to 23.29 USD.
- Latest quarter (Q2 FY2026, ended June 30, 2026): revenue $0.00, net loss $61.8M, diluted EPS (earnings per share) of -0.84.
- Balance sheet (June 30, 2026): cash and short-term investments of $537.0M against total debt of $101.5M.
- Next earnings date: Nov. 4, 2026, with an EPS estimate of -0.77.
What happened
On Thursday, Oct. 22, 2026, Benzinga published a piece titled "What's Going On with MoonLake Immunotherapeutics Stock on Thursday?" It reported that MLTX was trading higher, with session volume far above the stock's average volume, according to Benzinga Pro data. Heavy volume means many more shares than usual changed hands.
The gain was 15.87% in one day. Measured from the Oct. 20 close, the two-session gain is 19.57%. Even after this rise, the share price of 12.34 USD sits well below the top of the 52-week range (23.29 USD) and not far above the low (9.31 USD).
This article reports the move as Benzinga described it: higher trading on heavy volume. We do not attach any other explanation to it.
Why it matters for investors
The business is pre-revenue. MoonLake reported $0.00 in revenue in each of the last five quarters on its income statement. One caveat: FMP's segment data lists license revenue of $299.6M for both Q2 FY2026 and Q2 FY2025, which conflicts with those income-statement figures. We use the income-statement figures and treat the segment line as a likely data inconsistency. For a company like this, the stock price depends on expectations about its future, not on current sales. That is why single-day moves can be large.
Losses have been steady, not accelerating. Here is the five-quarter trend in net income:
- Q2 FY2025 (ended June 30, 2025): $-55.2M
- Q3 FY2025 (ended Sept. 30, 2025): $-69.7M
- Q4 FY2025 (ended Dec. 31, 2025): $-62.4M
- Q1 FY2026 (ended March 31, 2026): $-69.7M
- Q2 FY2026 (ended June 30, 2026): $-61.8M
Cash burn is the number to follow. Free cash flow (cash from operations minus capital spending) was negative in every quarter, and capital spending was $0.00. By quarter, newest first: $-55.6M (Q2 FY2026), $-66.3M (Q1 FY2026), $-58.8M (Q4 FY2025), $-44.5M (Q3 FY2025) and $-54.5M (Q2 FY2025). The latest figure was the third-lowest burn of the five quarters and lower than the prior quarter's $66.3M.
The balance sheet gives room. As of June 30, 2026, cash and short-term investments were $537.0M, total debt was $101.5M, and net debt was $-376.4M. A negative net debt figure means cash exceeds debt. Shareholders' equity was $428.2M, and debt-to-equity was 0.24.
Earnings beat the estimate on paper. For Q2 FY2026, reported EPS of -0.84 was better than the analyst estimate of -0.90859, a difference of +$0.07 (7.5%). For a company with no revenue, a "beat" means a smaller-than-expected loss.
Analysts are positive; the model is not. According to FMP data, 19 analysts rate the stock: 15 Buy, 2 Hold and 2 Sell, for a consensus of "Buy." The consensus price target is 50.00 USD, with the average, median, high and low all at that same figure, so the target range is a single point. HC Wainwright & Co. maintained its Buy rating on Oct. 5, 2026. By contrast, FMP's discounted cash flow model (an estimate of value based on projected future cash) gives 4.08 USD per share. The two views are far apart, which shows how much depends on assumptions for a company without revenue.
Peers. Compared with other small biotechs, MoonLake is the second-largest in this group by market cap:
| Company | Market cap | P/E (trailing 12 months) | Net margin | |---|---|---|---| | MoonLake (MLTX) | $1.05B | -3.21 | n/m | | Aclaris Therapeutics (ACRS) | $563.8M | -6.60 | -921.5% | | Alumis (ALMS) | $882.7M | -1.79 | -5933.5% | | AnaptysBio (ANAB) | $1.44B | 7.13 | 82.4% | | Attovia Therapeutics (ATTO) | $661.9M | -15.59 | -8742.9% |
n/m means not meaningful, because MoonLake's revenue is zero. A negative P/E (price relative to earnings) means the company lost money, so it is not a useful valuation yardstick here. Only AnaptysBio shows a positive P/E and net margin in this group.
Our MoonshotScore. Stock Expert AI's MoonshotScore V2 for MLTX is 45.1, rated "Fair." The sector-relative pillars are: growth 13, momentum 35, quality 34, safety 41 and valuation 36. Growth is the weakest pillar, which fits a company with no revenue. Safety is the highest. None of the pillars is strong.
What could go wrong
- Continuing losses. The company has lost money every quarter in the five-quarter window and has no revenue to offset it.
- Weak financial-strength scores. The Piotroski score (a 0-9 health check) is 1, and the Altman Z-score (a bankruptcy-risk gauge) is 1.92. Both are low, although the Altman model was designed for operating companies, not pre-revenue biotechs.
- Insider activity. Among the 30 most recent Form 4 filings (insider trade reports), those dated in the last 90 days show 0 open-market purchases and 1 sale. Older filings in that window may be missing.
- Volatility. The stock has traded between 9.31 and 23.29 USD in 52 weeks. A two-session gain can reverse.
- Analyst targets are not guarantees. The 50.00 USD consensus target is the analysts' view, not a forecast from us.
What to watch next
- Nov. 4, 2026: the next earnings date. The EPS estimate is -0.77.
- Following quarters: analysts expect EPS of -0.88 for the period ending March 30, 2027 and -0.83 for the period ending June 30, 2027 (3 analysts each).
- Cash burn and cash balance: whether free cash flow stays near recent levels and how the $537.0M cash figure changes.
- Volume: whether trading stays above its average level in the coming sessions.
- Company statements: any release from MoonLake that explains its plans in more detail.
Frequently asked questions
Q: Why did MoonLake Immunotherapeutics stock rise on Oct. 22, 2026?
According to Benzinga, citing Benzinga Pro data, MLTX traded higher on Thursday, Oct. 22, 2026, on session volume well above its average. The stock was at 12.34 USD on the latest quote, up 15.87% on the day and 19.57% from the Oct. 20 close.
Q: Does MoonLake make money?
No. In the quarter ended June 30, 2026, revenue was $0.00 and net income was a loss of $61.8M, or -0.84 per share. The company had $537.0M in cash and short-term investments at quarter end, which funds its operations.
Q: What do analysts expect for MLTX?
Of 19 analysts, 15 rate it Buy, 2 Hold and 2 Sell. The consensus price target is 50.00 USD, with the high and low targets identical. These are analyst opinions, not our forecast, and the stock was at 12.34 USD on Oct. 22, 2026. This article is information, not investment advice.
This is educational content, not investment advice. Past performance does not guarantee future results.